Doing Business the Japanese Way

Posted:
11
August 2004

Dr Lorch (second from left) and Dr Täubel (third from left) visiting business partners in Japan

Our Managing Director Dr Jörg Täubel and Medical Director Dr Ulrike Lorch recently travelled to Japan to meet with business partners and learn more about the Japanese way of doing business.Nemawashi is a Japanese business process which assures a consensus and harmony between business partners. Nemawashi allows both parties to save valuable time before important meetings because both sides are able to adjust opinions and positions beforehand.

Dr Täubel (second from left) and Dr Lorch (third from left) visiting business partners in Japan

Dr Täubel and Dr Lorch gained first hand experience of Nemawashi during the week-long trip, during which time they met with a range of policy makers, media and business partners to gain further insights into the Japanese CRO and SMO markets.“The trip was a huge success” said Dr Lorch. “Not only did we hold very positive meetings with stakeholders, we also discovered a new and exciting way of life. I have started learning Japanese to help develop relations with our partners in future!”

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more